Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2010

View Archived Issues

RNA-based therapeutics abrogate Ebola and Marburg virus infections in primates

NexMed and Bio-Quant present preclinical data on PrevOnco

E-6005 improves pruritus and inflammation in preclinical tests

Namisol tablet for multiple sclerosis shows promise in first-in-human trial

PLX-4032 shows promise to treat BRAF mutation-positive melanoma

Walter Chilcott acquires U.S. rights to Enablex from Novartis

New oral contraceptive Beyaz receives FDA approval

CHMP recommends approval of Tasigna in E.U. as first-line therapy for Ph+ CML

DSM and Crucell agree to expand Percivia PER.C6 joint venture

FDA approves Allergan's Ozurdex implants for noninfectious uveitis

CHMP recommends approval of TOBI Podhaler for cystic fibrosis

Rosiglitazone-containing diabetes medicines suspended in Europe, restricted in U.S.

Phenex Pharma receives financing for FXR and RORgt R&D programs

CHMP finds no causal relationship between GSK's Pandemrix vaccine and narcolepsy

MRC Technology patents novel protein kinase inhibitors

Inovio completes enrollment in Pennvax-B DNA vaccine trial

AstraZeneca's phase III zibotentan trial in CRPC does not meet primary endpoint

Boehringer Ingelheim identifies new mPGES-1 inhibitors

FDA accepts Bionovo's manufacturing plan for Menerba

Ligand Pharma claims new prostanoid DP2 receptor antagonists

Centocor Ortho Biotech seeks to expand Simponi label in rheumatoid arthritis

FDA grants priority review for Endo Pharma's NDA for crush-resistant oral oxymorphone

Takeda investigators describe new inhibitors of CDC7-related protein kinase

Wyeth's commercialization of Relistor extended in U.S.

Pfizer researchers claim novel gamma-secretase modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...